Novavax & Gavi Execute Advance Purchase Agreement for COVID-19 Vaccine for COVAX Facility
Novavax, a biotechnology company developing next-generation vaccines for serious infectious diseases has announced that it has finalized an advance purchase agreement (APA) with Gavi, the Vaccine Alliance (Gavi) for the supply of its recombinant protein-based COVID-19 vaccine candidate to the COVAX Facility. Under the APA, Novavax is expected to manufacture and distribute 350 million doses…